All In Biotech

Drug Trial Radar · NCT04587479

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Nov 23, 2020

Primary completion

Oct 31, 2024

Study completion Oct 31, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.

Conditions

  • Solid Tumors, Adult

Interventions

  • JAB-8263Drug

    Variable dose, orally Q2D with 28 days each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicitiesTime frame: Approximately 2.5 years
  2. Find Recommended Phase 2 Dose (RP2D) of JAB-8263Time frame: Approximately 2.5 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • SCRI HeatlthONE

    Denver, Colorado

  • Florida Cancer Center, Lake Mary

    Lake City, Florida

  • Tennessee Oncology Nashville

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.